The Application of a Safe Neutralization Assay for Ebola Virus Using Lentivirus-Based Pseudotyped Virus

Cao, Zongjie; Jin, Hongli; Wong, Gary; Zhang, Ying; Jiao, Cuicui; Feng, Na; Wu, Fangfang; Xu, Shengnan; Chi, Hang; Zhao, Yongkun; Wang, Tiecheng; Sun, Wenzhao; Gao, Yuwei; Wang, Cuiling; Xia, Xianzhu; Wang, Hualei

doi:10.1007/s12250-021-00405-8

Cited by 6 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For viruses such as EBOV, all experiments should be performed under a biosafety laboratory (BSL)-4 conditions, which are limited in availability and expensive to operate [45]. Thus, it is beneficial to use alternative neutralization assays that do not require viruses or live cells, and that can be performed in BSL-2 laboratories to assess neutralizing antibody capacity [44, 46]. These alternative assays should conclude if a person with high binding antibodies against EBOV (based on FANG ELISA or Luminex) was indeed infected with the virus (although some level of cross-reactivity can never be ruled out) [29].…”

Section: Discussionmentioning

confidence: 99%

Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo

Matuvanga

Mariën

Larivière

et al. 2023

Preprint

View full text Add to dashboard Cite

IntroductionA serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens.MethodsSerum samples were collected in a cohort of HCPs and frontliners (n=698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay.ResultsThe seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7-2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0 - 1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9) samples using FANG ELISA.ConclusionIn contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.

show abstract

Section: Discussionmentioning

confidence: 99%

Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo

Matuvanga

Mariën

Larivière

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The characterization of pseudoviral particles was carried out by verifying the expression of the reporter gene through transduction into Vero-E6 or MDCK cells. Additionally, lentivirus-based pseudotypes were developed to study Ebola virus entry and bear GP glycoprotein on the surface, as detailed by Cao and coauthors [28]. The characterization of pseudotyped EBOV included electron microscopy of pseudo-EBOV and the quantification of relative light units (RLUs).…”

Section: The Human Immunodeficiency Virus (Hiv-1)-based Lentiviral Pa...mentioning

confidence: 99%

“…Researchers evaluated the effectiveness of HIV entry inhibitors against MERS-CoV pseudovirus infection. They discovered that small molecules, ADS-J1, and 3-hydroxyphthalic anhydride-modified human serum albumin (HP-HSA), demonstrated significant inhibition of MERS-CoV pseudovirus infection [28]. Recently, HIV inhibitor molecules have been tested as inhibitors of SARS-CoV-2 variants.…”

Section: Screening Of Entry Inhibitorsmentioning

confidence: 99%

Pseudovirus-Based Systems for Screening Natural Antiviral Agents: A Comprehensive Review

Trischitta,

Tamburello,

Venuti

et al. 2024

IJMS

View full text Add to dashboard Cite

Since the outbreak of COVID-19, researchers have been working tirelessly to discover effective ways to combat coronavirus infection. The use of computational drug repurposing methods and molecular docking has been instrumental in identifying compounds that have the potential to disrupt the binding between the spike glycoprotein of SARS-CoV-2 and human ACE2 (hACE2). Moreover, the pseudovirus approach has emerged as a robust technique for investigating the mechanism of virus attachment to cellular receptors and for screening targeted small molecule drugs. Pseudoviruses are viral particles containing envelope proteins, which mediate the virus’s entry with the same efficiency as that of live viruses but lacking pathogenic genes. Therefore, they represent a safe alternative to screen potential drugs inhibiting viral entry, especially for highly pathogenic enveloped viruses. In this review, we have compiled a list of antiviral plant extracts and natural products that have been extensively studied against enveloped emerging and re-emerging viruses by pseudovirus technology. The review is organized into three parts: (1) construction of pseudoviruses based on different packaging systems and applications; (2) knowledge of emerging and re-emerging viruses; (3) natural products active against pseudovirus-mediated entry. One of the most crucial stages in the life cycle of a virus is its penetration into host cells. Therefore, the discovery of viral entry inhibitors represents a promising therapeutic option in fighting against emerging viruses.

show abstract

“…Te human immunodefciency virus-based pseudovirion containing the SUDV GP or EBOV GP was generated as previously described [38]. Briefy, 293 T cells were cotransfected with the Env-defective HIV backbone plasmid, pNL4-3.Luc.RE, and the plasmid pcDNA4.0-SUDV-GP or pcDNA4.0-EBOV-GP contained the SUDV GP or EBOV GP genes, respectively.…”

Section: Pseudovirion Neutralization Assaymentioning

confidence: 99%

A Bivalent Bacterium-like Particles-Based Vaccine Induced Potent Immune Responses against the Sudan Virus and Ebola Virus in Mice

Jiao

et al. 2023

Transboundary and Emerging Diseases

Self Cite

View full text Add to dashboard Cite

Ebola virus disease (EVD) is an acute viral hemorrhagic fever disease causing thousands of deaths. The large Ebola outbreak in 2014–2016 posed significant threats to global public health, requiring the development of multiple medical measures for disease control. Sudan virus (SUDV) and Zaire virus (EBOV) are responsible for severe disease and occasional deadly outbreaks in West Africa and Middle Africa. This study shows that bivalent bacterium-like particles (BLPs)-based vaccine, SUDV-EBOV BLPs (S/ZBLP + 2 + P), generated by mixing SUDV-BLPs and EBOV-BLPs at a 1 : 1 ratio, is immunogenic in mice. The SUDV-EBOV BLPs induced potent immune responses against SUDV and EBOV and elicited both T-helper 1 (Th1) and T-helper 2 (Th2) immune responses. The results indicated that SUDV-EBOV BLPs-based vaccine has the potential to be a promising candidate against SUDV and EBOV infections and provide a strategy to develop universal vaccines for EVD.

show abstract

The Application of a Safe Neutralization Assay for Ebola Virus Using Lentivirus-Based Pseudotyped Virus

Cited by 6 publications

References 6 publications

Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo

Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo

Pseudovirus-Based Systems for Screening Natural Antiviral Agents: A Comprehensive Review

A Bivalent Bacterium-like Particles-Based Vaccine Induced Potent Immune Responses against the Sudan Virus and Ebola Virus in Mice

Contact Info

Product

Resources

About